胡雄 ?? 奇口服液治疗腹的刺激性肠综合征:一个多中心,双盲,随机对照试验
Xiaohui Guo1, Ting Cheng2, Meiling Xuan1
1Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
概括
黄翔基 (HXZQ) 口服液显著改善了腹性易怒肠综合征 (IBS-D) 患者的充分缓解和症状严重程度. 这项研究提供了HXZQ作为IBS-D的潜在治疗选择的证据.
科学领域:
- 胃肠病学 胃肠病学
- 传统中国医药 传统中国医药
- 临床药理学 临床药理学
背景情况:
- 临床前和临床研究表明,Huoxiang Zhengqi (HXZQ) 口服液体对胃肠道疾病有好处.
- 在患有腹 (IBS-D) 的刺激性肠综合征患者中,HXZQ的强有力的证据有限.
研究的目的:
- 评估HXZQ口服液在被诊断为IBS-D的患者的疗效和安全性.
- 为HXZQ在管理IBS-D.提供强有力的临床证据.
主要方法:
- 进行了一项多中心,双盲,随机对照试验.
- 成年IBS-D患者每天两次接受HXZQ口服液或安慰剂,持续4周.
- 主要结局是充分缓解 (AR) 响应率;次要结局包括IBS-SSS,IBS-QOL和EQ-5D-5L分数.
主要成果:
- 与安慰剂组相比,HXZQ组的AR响应率显著更高 (率差:0.29).
- 治疗HXZQ导致IBS症状严重程度等级 (IBS-SSS) 的得分降低得多.
- 在试验期间没有报告任何严重不良事件.
结论:
- HXZQ口服液在治疗IBS-D方面显示出有效性和安全性.
- 在临床实践中,HXZQ可以作为IBS-D患者的有价值的替代治疗方法.
更多相关视频
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome III: Medical and Nursing Management
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...


